Related Experiment Video
Updated: Jul 25, 2026

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration
Published on: May 4, 2017
Alpha 1-antitrypsin serum levels in widespread bronchiectasis.
F A el-Kassimi1, A S Warsy, A Uz-Zaman
1Medical Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Higher serum alpha 1-antitrypsin (alpha 1-AT) levels were observed in bronchiectasis patients, potentially indicating an acute phase response to infection rather than alpha 1-AT deficiency. Further research is needed to confirm this finding.
Area of Science:
- Pulmonology
- Genetics
- Clinical Medicine
Background:
- Alpha 1-antitrypsin (alpha 1-AT) deficiency is a known risk factor for emphysema.
- Previous reports suggest a link between alpha 1-AT deficiency and bronchiectasis, but this association is debated due to confounding factors.
- The role of alpha 1-AT in the pathogenesis of bronchiectasis remains unclear.
Purpose of the Study:
- To investigate serum alpha 1-antitrypsin levels in patients with widespread bronchiectasis.
- To explore the potential relationship between alpha 1-AT levels and bronchiectasis, contrasting with previous findings.
Main Methods:
- Serum samples were collected from 35 patients diagnosed with widespread bronchiectasis.
- Serum alpha 1-AT levels were measured and compared to those of healthy controls.
Main Results:
- Patients with bronchiectasis exhibited significantly higher serum alpha 1-AT levels compared to healthy controls.
- These findings contradict previous studies suggesting an association between alpha 1-AT deficiency and bronchiectasis.
Conclusions:
- Elevated serum alpha 1-AT in bronchiectasis patients may represent a non-specific acute phase reactant response to bronchial infection.
- Further investigation is required to determine if bronchiectasis can be a manifestation of alpha 1-AT deficiency, similar to emphysema.
More Related Videos
03:38Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
05:45A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Related Concept Videos
Pneumonia III: Complications and Assessment
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Asthma III: Clinical Manifestations
Chronic Obstructive Pulmonary Disease II: Emphysema
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations